• One Health
  • Pain Management
  • Oncology
  • Anesthesia
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

AU researchers study new canine lymphoma treatment

Article

AUBURN, AL -11/14/06 - Auburn University veterinary researchers received a $1.4-million National Cancer Institute grant to study targeted gene therapy for lymphoma, a project that could change the treatment regimens for dogs and humans.

AUBURN, AL -11/14/06 - Auburn University veterinary researchers  received a $1.4-million National Cancer Institute grant to study targeted gene therapy for lymphoma, a project that could change the treatment regimens for dogs and humans.

 

Dr. Bruce Smith of the College of Veterinary Medicine's Scott-Ritchey Research Center is leading an interdisciplinary team that will administer a genetically altered, non-replicating virus to lymphoma-affected dogs, followed by a drug that seeks out and kills the virus-infected cancer cells.

 

“Gene therapy is becoming more common in medical research, but what makes Auburn's research unique is that we are modifying the virus to target, or specifically infect, the lymphoma tumor cell,” Smith says. “We have also altered the virus so that it encodes a protein, which, when it comes in contact with the drug, converts the drug into a toxic substance and that toxin kills the lymphoma cell.”

The grant from the National Cancer Institute, part of the National Institutes of Health, covers five years at Auburn, including two years of laboratory work developing gene vectors and testing them on cells, followed by three years of clinical trials with dogs diagnosed with lymphoma.

Related Videos
062018_cyberbullying-220_kjames.png
big-hand-cutting-the-wire-450px-shutterstock-568795309.jpg
© 2024 MJH Life Sciences

All rights reserved.